MedTrace Logo

Evaluate the Efficacy and Safety of Azvudine in Preventing SARS-Cov-2 Infection in Household Contacts of Covid-19

NCT05633433 · Status: UNKNOWN · Phase: PHASE2/PHASE3 · Type: INTERVENTIONAL · Enrollment: 1550

Last updated 2023-01-09

No results posted yet for this study

Summary

A Phase II/III Randomized, Double-Blind, Placebo-Controlled Trial to Evaluate the Efficacy and Safety of Azvudine in Preventing SARS-Cov-2 Infection in Household Contacts of Individuals Infected with SARS-CoV-2

Conditions

Interventions

DRUG

Azvudine

Azvudine is a novel nucleoside reverse transcriptase inhibitor.

DRUG

Placebo

Placebo

Sponsors & Collaborators

  • Shanghai Fosun Pharmaceutical Industrial Development Co. Ltd.

    collaborator INDUSTRY

  • Henan Genuine Biotech Co., Ltd.

    collaborator INDUSTRY

  • Shanghai Henlius Biotech

    lead INDUSTRY

Principal Investigators

  • Gerard S. Garcia, M.D. · Cebu Doctor's University Hospital

Study Design

Allocation
RANDOMIZED
Purpose
PREVENTION
Masking
QUADRUPLE
Model
PARALLEL

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
Yes

Timeline & Regulatory

Start
2022-12-29
Primary Completion
2024-06-15
Completion
2024-07-15

Countries

  • Malaysia
  • Philippines

Study Locations

More Related Trials

Entities

Drugs
Diseases
Companies

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT05633433 on ClinicalTrials.gov